Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioma 3Oligodendroglioma 2Gliosarcoma 2Glioma, Subependymal 2Glioblastoma 2Ependymoma 2Astrocytoma 2Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Pinealoma 1Pancreatic Neoplasms 1Pancreatic Intraductal Neoplasms 1Neuroectodermal Tumors, Primitive 1Meningioma 1Medulloblastoma 1Healthy, no Evidence of Disease 1Diffuse Intrinsic Pontine Glioma 1Craniopharyngioma 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Endometrioid 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Recurrence × Congresses as Topic × Clear all
NCT03690869 2025-04-08

REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma

Regeneron Pharmaceuticals

Phase 1/2 Terminated
57 enrolled 31 charts
CNS

Diffuse Intrinsic Pontine Glioma, Glioma, Recurrence, Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡